ArticleMolecular medicine reports2016
Oncogenic role of microRNA‑20a in human uveal melanoma.
Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Blood-based circulating microRNAs as diagnostic biomarkers in cutaneous melanoma: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Exploring of miR-155-5p, miR-181b-5p, and miR-454-3p Expressions in Circulating Cell-Free RNA: Insights from Peripheral Blood of Uveal Malignant Melanoma Patients.Biochemical genetics · 2025Article
- PLEK2: a potential biomarker for metastasis and prognostic evaluation in uveal melanoma.Frontiers in medicine · 2024Article
- Genetic and Epigenetic Features of Uveal Melanoma-An Overview and Clinical Implications.International journal of molecular sciences · 2023Review
- Genetics and RNA Regulation of Uveal Melanoma.Cancers · 2023Review
- RETRACTED: Expression of microRNAs and their target genes in melanomas originating from gynecologic sites.PloS one · 2023Article
- Development of a 3-MicroRNA Signature and Nomogram for Predicting the Survival of Patients with Uveal Melanoma Based on TCGA and GEO Databases.Journal of ophthalmology · 2022Article
- Genetic Basis and Molecular Mechanisms of Uveal Melanoma Metastasis: A Focus on Prognosis.Frontiers in oncology · 2022Review
- Current molecular and clinical insights into uveal melanoma (Review).International journal of oncology · 2021Review
- MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.Frontiers in oncology · 2021Review
- Emerging roles of microRNAs and their implications in uveal melanoma.Cellular and molecular life sciences : CMLS · 2021Review
- The Role of Non-Coding RNAs in Uveal Melanoma.Cancers · 2020Review
- MicroRNAs and Uveal Melanoma: Understanding the Diverse Role of These Small Molecular Regulators.International journal of molecular sciences · 2020Review
- A Review of MicroRNA in Uveal Melanoma.OncoTargets and therapy · 2020Review
- Association of microRNA-423 rs6505162 C>A polymorphism with susceptibility and metastasis of colorectal carcinoma.Medicine · 2018Article
- The miR-181 family promotes cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor in uveal melanoma.Journal of experimental & clinical cancer research : CR · 2018Article
- Expression, regulation and mechanism of action of the miR-17-92 cluster in tumor cells (Review).International journal of molecular medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a member of the microRNA (miR)-17-92 cluster, miR‑20a has been indicated to be involved in the regulation of the proliferation and invasion of various cancer cells. Previous studies have observed elevated plasma levels of miR‑20a in patients with uveal melanoma (UM), compared with normal controls. In the present study, the potential function of miR‑20a in UM was investigated. Reverse transcription‑quantitative polymerase chain reaction analysis was performed to detect the expression levels of miR‑20a in UM cells and tissues. The functions of miR‑20a on cell proliferation, migration and invasion were determined in vitro using 3‑(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide and Transwell assays, respectively. The expression levels of miR‑20a were significantly increased in the UM cells and tissues (P<0.05). Subsequently, miR‑20a mimics were transfected into UM cells, which led to increases in cell growth, migration and invasion activities. By contrast, miR‑20a inhibition markedly suppressed the viability and motility of UM cells in vitro. These data provided convincing evidence that miR‑20a may function as an oncogenic miRNA, and may be involved in promoting cell growth and motility in the molecular etiology of UM, suggesting its potential as a candidate therapeutic target for the treatment of patients with UM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.